Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain ...
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin’s therapeutic window …